Letter to the Editor
A novel FTL mutation responsible for neuroferritinopathy with asymmetric clinical features and brain anomalies

https://doi.org/10.1016/j.parkreldis.2014.04.026Get rights and content

Section snippets

Acknowledgments

We are grateful to the patient for his participation to this study.

References (5)

  • P. Dusek et al.

    Iron dysregulation in movement disorders

    Neurobiol Dis

    (2012)
  • P.F. Chinnery et al.

    Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation

    Brain

    (2007)
There are more references available in the full text version of this article.

Cited by (11)

  • Iron Metabolism and Related Disorders

    2020, Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics: Metabolic Disorders
  • Neuroferritinopathy: From ferritin structure modification to pathogenetic mechanism

    2015, Neurobiology of Disease
    Citation Excerpt :

    Subsequently, other cases were described in different parts of the world. Up to now, other 8 types of mutations have been identified in different ethnic groups (Vidal et al., 2003); (Mancuso et al., 2005);(Maciel et al., 2005); (Ohta et al., 2008); (Kubota et al., 2009); (Devos et al., 2009; Moutton et al., 2014; Nishida et al., 2014; Storti et al., 2013); they are reported in Table 1, adopting the HGVS nomenclature (den Dunnen and Antonarakis, 2000 and www.hgvs.org/mutnomen). The FTL1 gene is located on chromosome 19q13.33 and it is composed by 4 exons and 3 introns.

  • Pathogenic mechanism and modeling of neuroferritinopathy

    2021, Cellular and Molecular Life Sciences
View all citing articles on Scopus
View full text